CELCUITY Aktie

>CELCUITY Aktienkurs

97.5 EUR +0.0% (TradegateBSX)

Ask: 98 EUR / 210 Stück

Bid: 97.5 EUR / 210 Stück

Tagesumsatz: 16 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CELCUITY Aktie über LYNX handeln

Intraday

1 Jahr

>CELCUITY Performance

1 Woche: +5,7%

1 Monat: +4,8%

3 Monate: +16,1%

6 Monate: +130,0%

1 Jahr: 0%

laufendes Jahr: +13,0%

>CELCUITY Aktie

Name:

CELCUITY INC. DL -,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US15102K1007 / A2JAAX

Symbol/ Ticker:

7VR (Frankfurt) / CELC (NASDAQ)

Kürzel:

FRA:7VR, ETR:7VR, 7VR:GR, NASDAQ:CELC

Index:

Webseite:

https://www.celcuity.com/

Profil:

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets ..
>Volltext..

Marktkapitalisierung:

4716.36 Mio. EUR

Unternehmenswert:

4612.75 Mio. EUR

Umsatz:

EBITDA:

-149.03 Mio. EUR

Nettogewinn:

-153.37 Mio. EUR

Gewinn je Aktie:

-3.28 EUR

Schulden:

278.87 Mio. EUR

Liquide Mittel:

143.55 Mio. EUR

Operativer Cashflow:

-132.79 Mio. EUR

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

-58.39%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 330.804 USD.

Suchwörter:

CELCUITY

Letzte Datenerhebung:

06.04.26

>CELCUITY Kennzahlen

Aktien/ Unternehmen:

Aktien: 48.34 Mio. St.

Frei handelbar: 78.23%

Leerverk. Aktien: 18.89%

Rückkaufquote: -2.53%

Mitarbeiter: 155

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 14.18%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 54.04

PEG-Ratio: -0.86

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -49.75%

Eigenkaprendite: -163.8%

>CELCUITY Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>CELCUITY Chart & Kurs - NASDAQ

>CELCUITY News

05.04.26 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Celcuity im Wert von 330804 USD (Insiderkauf)
	Buller, Richard E. - Aufsichtsrat - Tag der Transaktion: 2026-03-31...

27.03.26 - 01:36	Why Celcuity Stock Popped Today (Fool)
	The cancer-focused biotech published its final set of figures for 2025....

26.03.26 - 01:21	Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 22:49	Earnings Call Transkript: Celcuity übertrifft Gewinnprognose für Q4 2025 – Aktie legt zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 21:09	Celcuity Non-GAAP EPS of -$0.73 beats by $0.28 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 21:06	Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments....

18.03.26 - 13:03

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call (GlobeNewswire EN)

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update....

13.03.26 - 16:00	Inside One Fund′s $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug (Fool)
	Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions....

10.03.26 - 23:42	Celcuity: Vielversprechende Studiendaten für Brustkrebsmedikament Gedatolisib (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.03.26 - 20:36	Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing (Fool)
	Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology....

09.03.26 - 22:45

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology (GlobeNewswire EN)

MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) PIK3CA WT advanced breast cancer (“ABC”), following progression on or after treatment with a CDK4/6 inhibitor and an aromatase inhibitor....

04.03.26 - 18:36	Celcuity auf der TD Cowen Konferenz: Strategische Einblicke zu Gedatolisib (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 09:51

XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 3 (XETRA)

US11259P1093 GB00BJQTGV64 PLIPOSA00010 PLICI0000010 US72815G1085 CA92537Y1043 SE0016802797 CA7480331072 SE0016843809 SE0015797873 CA89602T1012 PLGDVIS00018 AU0000157455 CA75103L3092 PLDGNST00012 CA02074J5017 US68235C2061 KYG2993S1066 JP3141600001 PLSFD0000013 JP3396000006 US82322J1079 IT0005499949 US8122152007 PLIMGPW00013 SE0004899474 SE0009920994 US15102K1007 CA3933801001 US7004021009 JP3966660007 GB00BVZNY531 GB00BNG59574 BE0974380124 AU0000134694 JP3480600000 JP3187000009 CY0103562118 PLBLKPC00014 CA6488301079 CNE100004JD2 IT0005442154 AU0000141533 US4652701065 GB00BMC2XX17 PLROCCA00013 SE0005676103 AU0000058943 GB00BF044593 AU0000129496 CNE100003FC4 PLSMFBC00016 CA75585H2063 MU0461N00015 CA5791761086 JP3548660004 JP3497400006 JP3896000001 CA57778R1001 CNE100006V73 JP3335410001 CA72583H1064 JP3880800002 KYG2163K1076 US0269481091 HK0000735800 PLAIRMK00017 PLFRENT00014 PLCRBON00018 AU0000177271 DK0061411964 CA3686501071 BMG916101576...

22.02.26 - 20:36	Celcuity Stock Soars 700% in a Year as One Investor′s $17 Million Buy Helps Create Top Two Position (Fool)
	Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology....

13.02.26 - 14:00	Soleus Adds a Significant Number of Celcuity Shares (Fool)
	This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment....

12.02.26 - 22:09

Celcuity Appoints Charles Romp to its Board of Directors (GlobeNewswire EN)

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting....

11.02.26 - 17:30	Celcuity vor Markteinführung von Gedatolisib: FDA-Entscheidung und Milliardenpotenzial im Fokus (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.02.26 - 22:48	Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump (Fool)
	Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance....

04.02.26 - 13:09	Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire EN)
	MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026....

30.01.26 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Celcuity im Wert von 2400538 USD (Insiderkauf)
	Dalvey, David - Aufsichtsrat - Tag der Transaktion: 2026-01-27...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram